Oct 30, 2019, 08:50
Carbiotix AB (publ) ("Carbiotix") announces today that the company will conduct an internal pilot study of its gut health testing services with Gebro Pharma AG Switzerland. The pilot study is planned for Q1 2020 and will serve to formulate a business model for a new collaborative service and roll out plan for 2021.
Gebro Pharma AG Switzerland is a subsidiary of Gebro Pharma (www.gebro.com/en/), a privately held Austrian company focusing on the development, manufacturing and sale of medicinal products in 25 countries. Gebro Pharma AG Switzerland is located in Liestal, near the city of Basel, and is focused on the marketing of medicinal products with close contact with pharmacies in diverse areas such as pain therapy, dermatology and paediatrics.
Kristofer Cook, CEO for Carbiotix, comments
“This pilot study is a key first step to formulating a business model and roll out plan for a collaborative service for the Swiss market, which will also have applications in other markets around the globe. We are moreover optimistic that this pilot study will lead to the identification of other business opportunities leveraging Carbiotix gut health testing and microbiome modulation platforms. We regard Gebro Pharma AG Switzerland as a progressive company in the pharmaceutical industry that understands the market potential of cost-effectively monitoring and improving gut health.”
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 30 October 2019.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Carbiotix AB (CRBX) (www.carbiotix.com) is a biotechnology company developing Microbiome Modulator Therapeutics (MMT) that amplify the production of key metabolites for the treatment of different metabolic and chronic diseases. The company’s therapeutics are based on a propriety AXOS soluble fiber, isolated bacterial strains, and innovative formulations, supported by cost effective gut health testing services used to regularly diagnose and monitor gut health, as well as dose therapeutics.Go Back